Comparison of drug therapy with percutaneous coronary intervention

Comparison of drug therapy with percutaneous coronary intervention in the treatment of chronic stable angina

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20211129053210N1

Enrollment

100

Registered

2021-12-19

Start date

2022-01-20

Completion date

Unknown

Last updated

2022-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Ischemic Heart Disease. Chronic ischemic heart disease, unspecified

Interventions

Intervention 1: Control group: Cardiac ischemia drugs. Intervention 2: Intervention group: Cardiac ischemia drugs with percutaneous coronary intervention.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: More than 70% stenosis in at least one coronary artery EF more than 30%

Exclusion criteria

Exclusion criteria: Resistant angina class IV Treatment-resistant heart failure Cardiogenic shock Anatomy inappropriate for PCI Chronic renal failure Proximal LAD obstruction triple vessel disease Diabetes, smoker

Design outcomes

Primary

Measure	Time frame
Quality of life: In terms of the patient's clinical symptoms and based on the chronic angina checklist. Timepoint: Measurement of quality of life at the beginning of the study and 6 months after the intervention. Method of measurement: Chronic angina checklist.	—

Secondary

Measure	Time frame
Go to the emergency room based on the patient's statements. Timepoint: Evaluation of emergency department visit 6 months after the intervention. Method of measurement: Based on the patient's statements.;Number of hospitalizations based on hospitalization documents. Timepoint: Evaluation of the number of hospitalizations 6 months after the intervention. Method of measurement: Based on hospitalization documents.;Function Class: Angina classification based on the New York Heart Association. Timepoint: Evaluation of class function at the beginning of the study and 6 months after the intervention. Method of measurement: Based on the patient's statements and New York Heart Association.;Ejection fraction based on echocardiographic findings. Timepoint: Ejection fraction at the beginning of the study and 6 months after the intervention. Method of measurement: Based on the patient's echocardiographic evidence.	—

Measure

Time frame

Go to the emergency room based on the patient's statements. Timepoint: Evaluation of emergency department visit 6 months after the intervention. Method of measurement: Based on the patient's statements.;Number of hospitalizations based on hospitalization documents. Timepoint: Evaluation of the number of hospitalizations 6 months after the intervention. Method of measurement: Based on hospitalization documents.;Function Class: Angina classification based on the New York Heart Association. Timepoint: Evaluation of class function at the beginning of the study and 6 months after the intervention. Method of measurement: Based on the patient's statements and New York Heart Association.;Ejection fraction based on echocardiographic findings. Timepoint: Ejection fraction at the beginning of the study and 6 months after the intervention. Method of measurement: Based on the patient's echocardiographic evidence.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahsa Movahedi

Hamedan University of Medical Sciences

mahsa.movahedi@ymail.com+98 81 3838 8078

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026